Breaking News Instant updates and real-time market news.

CALA

Calithera Biosciences

$6.45

0.6 (10.26%)

08:38
01/13/20
01/13
08:38
01/13/20
08:38

Calithera Biosciences announces 2020 milestones

Calithera expects to achieve the following milestones in 2020: Announce topline data from randomized CANTATA trial of telaglenastat with cabozantinib in advanced renal cell carcinoma. The CANTATA trial is a global, randomized, double-blind clinical trial of telaglenastat combined with cabozantinib, in patients with advanced or metastatic RCC who have received one or two prior treatments. The CANTATA trial enrolled 445 patients at multiple centers globally. The primary endpoint is progression-free survival. Calithera plans to report top-line efficacy and safety data from the trial in the second half of 2020. Initiate Phase 2 trial of telaglenastat in non-small cell lung cancer patients with genetic mutation NRF2/KEAP1. The NRF2/KEAP1 pathway is known to drive the development of certain cancers, including a significant proportion of NSCLC through the regulation of reactive oxygen species in a manner that is dependent upon glutaminase activity. Recently presented clinical data demonstrate that activation of this pathway, either through the loss of KEAP1 function or activation of NRF2, results in very poor outcomes in NSCLC patients. The clear mechanistic rationale, strong preclinical data, and high unmet medical need in the NSCLC population have led Calithera to design a clinical study that will evaluate telaglenastat in combination with chemo-immunotherapy in first line NSCLC patients with tumors that harbor mutations in either KEAP1 or NRF2 that activate this pathway. This trial is expected to begin in the first half of 2020. Enroll telaglenastat combination trials in collaboration with Pfizer. Calithera and Pfizer have two clinical trial collaborations to evaluate Pfizer's CDK4/6 inhibitor palbociclib, also known as IBRANCE, and the dual-mechanism poly polymerase inhibitor talazoparib, also known as TALZENNA, each in combination with glutaminase inhibitor telaglenastat. Continue enrollment of multiple clinical trials evaluating Calithera's arginase inhibitor INCB001158. INCB001158 is a small-molecule immuno-oncology therapeutic being evaluated in multiple clinical trials as a single-agent and in combination with immunotherapies and chemotherapy for the treatment of patients with cancer. INCB001158 is being developed as part of a collaboration and license agreement with Incyte. Enroll clinical dose escalation trial evaluating CB-280, an oral arginase inhibitor, in cystic fibrosis. Arginase is believed to be critical in the pathology of cystic fibrosis. It impairs production of nitric oxide and generates metabolites of arginine that may impair lung function. A Phase 1b clinical study in people with CF, which is expected to start enrollment in the first half of 2020, will test multiple doses of CB-280 compared to placebo in approximately 30 adults with CF to determine a safe dose range, and pharmacodynamics effects of arginase inhibition in this population. Patients with any CF transmembrane conductance regulator mutational status will be eligible for the study.

  • 13

    Feb

CALA Calithera Biosciences
$6.45

0.6 (10.26%)

05/30/19
SBSH
05/30/19
INITIATION
Target $10
SBSH
Buy
Calithera Biosciences assumed with a Buy at Citi
Citi analyst Mohit Bansal assumed coverage Calithera Biosciences with a Buy rating and $10 price target. Under a prior analyst, Citi had a Buy rating on the shares with a $7 price target. Positive data mid-year from the small metastatic renal cell carcinoma trial could have read-through to the Cabo trial, Bansal tells investors in a research note.
11/19/19
HCWC
11/19/19
INITIATION
Target $7
HCWC
Buy
Calithera Biosciences initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth initiated coverage of Calithera Biosciences with a Buy rating and $7 price target. The company's lead product, telaglenastat, is a first-in-class, small molecule, oral glutaminase inhibitor for the treatment of kidney cancer, or renal cell carcinoma, Ramakanth tells investors in a research note. The analyst adds that pivotal clinical results are expected in 2020.

TODAY'S FREE FLY STORIES

INSG

Inseego

$9.23

0.76 (8.97%)

14:25
01/17/20
01/17
14:25
01/17/20
14:25
Options
Inseego call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSTG

NanoString

$30.44

-0.41 (-1.33%)

14:23
01/17/20
01/17
14:23
01/17/20
14:23
Hot Stocks
Pura Vida reports 5.37% passive stake in NanoString »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
01/17/20
01/17
14:17
01/17/20
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
01/17/20
01/17
14:16
01/17/20
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENV

Envestnet

$70.39

-4.05 (-5.44%)

14:06
01/17/20
01/17
14:06
01/17/20
14:06
Hot Stocks
Lawmakers urge FTC to investigate Envestnet over sale of financial data »

Several U.S. lawmakers,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

SNCA

Seneca Biopharma

$3.80

2.55 (204.00%)

14:06
01/17/20
01/17
14:06
01/17/20
14:06
Syndicate
Seneca Biopharma announces exercise of warrants for $7.55M gross proceeds »

Seneca Biopharma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DHT

DHT Holdings

$7.41

0.19 (2.63%)

14:05
01/17/20
01/17
14:05
01/17/20
14:05
Options
DHT Holdings call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:05
01/17/20
01/17
14:05
01/17/20
14:05
General news
Action Economics Survey results: »

Action Economics Survey…

BGNE

BeiGene

$169.60

1.72 (1.02%)

14:03
01/17/20
01/17
14:03
01/17/20
14:03
Upgrade
BeiGene rating change  »

BeiGene upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

SNE

Sony

$72.46

-0.09 (-0.12%)

, CMCSA

Comcast

$47.43

0.57 (1.22%)

13:57
01/17/20
01/17
13:57
01/17/20
13:57
On The Fly
Box Office Battle: 'Bad Boys for Life' opens strong »

Welcome to "Box Office…

SNE

Sony

$72.46

-0.09 (-0.12%)

CMCSA

Comcast

$47.43

0.57 (1.22%)

CMCSK

Comcast

$0.00

(0.00%)

T

AT&T

$38.33

0.3 (0.79%)

DIS

Disney

$144.67

-0.43 (-0.30%)

LGF.A

Lionsgate

$10.94

-0.34 (-3.01%)

LGF.B

Lionsgate

$10.30

-0.325 (-3.06%)

VIAC

ViacomCBS

$39.64

-0.41 (-1.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 29

    Jan

  • 04

    Feb

  • 04

    Feb

  • 06

    Feb

  • 06

    Feb

BA

Boeing

$325.18

-6.82 (-2.05%)

13:46
01/17/20
01/17
13:46
01/17/20
13:46
Periodicals
Boeing tells CNBC 'making necessary updates' to MAX after report of new issue »

After ABC's David…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

BA

Boeing

$326.24

-5.76 (-1.73%)

13:43
01/17/20
01/17
13:43
01/17/20
13:43
Hot Stocks
Breaking Hot Stocks news story on Boeing »

Boeing down 2% to $325.88…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

VB

Vanguard Small-Cap Index Fund

$169.72

-0.13 (-0.08%)

, IVV

iShares Core S&P 500

$333.10

0.72 (0.22%)

13:43
01/17/20
01/17
13:43
01/17/20
13:43
Technical Analysis
On The Fly: ETF fund flow highlights »

For the week creations…

VB

Vanguard Small-Cap Index Fund

$169.72

-0.13 (-0.08%)

IVV

iShares Core S&P 500

$333.10

0.72 (0.22%)

TLT

iShares 20+ Year Treasury Bond Fund

$138.05

-1.15 (-0.83%)

ESGU

iShares ESG MSCI U.S.A. ETF

$73.74

0.27 (0.37%)

VCSH

Vanguard Short-Term Corporate Bond Index Fund

$81.21

0.025 (0.03%)

SPY

SPDR S&P 500 ETF Trust

$331.63

0.73 (0.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$326.27

-5.73 (-1.73%)

13:42
01/17/20
01/17
13:42
01/17/20
13:42
Periodicals
ABC learns of another software issue with Boeing 737 Max »

ABC's David Kerley…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

JNJ

Johnson & Johnson

$148.97

0.72 (0.49%)

13:39
01/17/20
01/17
13:39
01/17/20
13:39
Periodicals
Judge slashes J&J verdict down to $6.8M from $8B in Risperdal suit, Law.com says »

Philadelphia Court of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 09

    Mar

  • 17

    Mar

JNJ

Johnson & Johnson

$149.03

0.78 (0.53%)

13:17
01/17/20
01/17
13:17
01/17/20
13:17
Periodicals
Judge cuts J&J punishment in Risperdal case to $6.8M from $8B, Bloomberg reports »

On October 8, 2019,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 09

    Mar

  • 17

    Mar

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
01/17/20
01/17
13:17
01/17/20
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
01/17/20
01/17
13:16
01/17/20
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BKR

Baker Hughes

$23.56

0.06 (0.26%)

13:04
01/17/20
01/17
13:04
01/17/20
13:04
Hot Stocks
Baker Hughes reports U.S. rig count up 15 to 796 rigs »

Baker Hughes reports that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 23

    Mar

MDR

McDermott

$0.73

0.0119 (1.66%)

13:02
01/17/20
01/17
13:02
01/17/20
13:02
Hot Stocks
McDermott announces start of commercial operation of Freeport LNG Train 2 »

McDermott International,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$240.69

0.17 (0.07%)

13:02
01/17/20
01/17
13:02
01/17/20
13:02
Recommendations
Amgen analyst commentary  »

Amgen raised prices today…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

BKR

Baker Hughes

$23.57

0.07 (0.30%)

13:01
01/17/20
01/17
13:01
01/17/20
13:01
Hot Stocks
Breaking Hot Stocks news story on Baker Hughes »

Baker Hughes reports U.S.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 23

    Mar

SNCA

Seneca Biopharma

$3.09

1.84 (147.20%)

12:59
01/17/20
01/17
12:59
01/17/20
12:59
Hot Stocks
Seneca Biopharma surges after saying talks starting with 'interested parties' »

Shares of micro-cap…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AUPH

Aurinia Pharmaceuticals

$20.02

0.19 (0.96%)

12:45
01/17/20
01/17
12:45
01/17/20
12:45
Options
Aurinia Pharmaceuticals call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:45
01/17/20
01/17
12:45
01/17/20
12:45
General news
Breaking General news story  »

Week of 1/17 Baker-Hughes…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.